29 May 2020 - - US-based stabilised hypochlorous acid products developer Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) and its partner, the MicroSafe Group, Dubai, have advanced their offering in Australia, the companies said.

MicroSafe Care Australia received approval for their patented and trademarked Nanocyn Disinfectant and Sanitizer, which is manufactured by Sonoma using its patented Microcyn Technology, to be entered into the Australian Register of Therapeutic Goods for use against SARS-CoV-2 (COVID-19).

Claims that a disinfectant has a virucidal effect must be expressly permitted by the Australian Therapeutic Goods Administration before being used in consumer advertising (including on the label) in Australia.

Recently, Sonoma announced that it had successfully closed an Asset Purchase Agreement with MicroSafe Group, for the exclusive rights of the Microcyn technology-based disinfectant for sale in the Australian market under the brand name Nanocyn and the European and Middle Eastern markets under the brand name MicroSafe.

Sonoma Pharmaceuticals is in developing and producing stabilised hypochlorous acid products for a wide range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions.

The company's products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties.

Sonoma's stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process.

The company's products are sold either directly or via partners in 53 countries worldwide and the company actively seeks new distribution partners.

The company has offices in Petaluma, California and Woodstock, Georgia, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

The MicroSafe Group has operations in several international countries with its head office in Dubai, United Arab Emirates.

With several regional offices in the Middle East, as well as MicroSafe Care Australia, MicroSafe Group is able to provide innovative solutions to a wide range of industries and healthcare providers.

The MicroSafe Group promotes only those products it believes will truly revolutionize healthcare products that will enrich the lives of patients and healthcare professionals all over the world.